• VIDAS® ToRC panel

VIDAS® ToRC panel

Serenity throughout pregnancy

The VIDAS® ToRC panel includes 9 automated tests for the screening and diagnosis of toxoplasmosis, rubella and cytomegalovirus (CMV) infections.

  • Complete solution
  • Proven high performance of IgG avidity tests
  • Cost-effective solution for small routine and confirmation testing
Add to my selection

Do you need more information

The VIDAS® ToRC panel is a complete solution for the diagnosis and follow-up of the most important materno-fetal infections in pregnant women and newborns. Toxoplasmosis, Rubella and Cytomegalovirus (ToRC) infections are generally benign diseases. However when women are infected during pregnancy, consequences for the fetus can be dramatic. Our value-added IgG avidity tests help distinguish between recent and past infection, thus reducing the number of amniocenteses, and avoiding unnecessary treatment and stress for the future mothers.

A complete solution

  • 3 markers for accurate diagnosis

IgG: IgGs are widely used to determine the presence of specific immunity.

IgM: If IgMs appear earlier than IgGs, they also disappear earlier. This makes IgMs an early and sensitive marker of acute infection.

IgG avidity:

IgGs are initially of low avidity, but will mature to high avidity a few months after primary infection. A high IgG avidity index thus allows to rule out recently-acquired infection.

Kinetics of  ToRC IgG and IgM antibodies and IgG avidity index

 

  • The VIDAS® ToRC solution
Toxoplasmosis Rubella Cytomegalovirus
VIDAS Toxo IgG II VIDAS Rub IgG VIDAS CMV IgG
VIDAS Toxo IgM VIDAS Rub IgM VIDAS CMV IgM
VIDAS Toxo Competition*   VIDAS CMV IgG Avidity II
VIDAS IgG Avidity    

* Toxo Competition: screens for Toxo IgG/IgM (total antibody). Optimal test for areas of low prevalence.
 

Highly performant IgG avidity tests

VIDAS® CMV IgG Avidity II

VIDAS CMV IgG Avidity II is a simple technique which enables weak avidity antibodies to be differentiated from high avidity antibodies. The detection of high avidity antibodies is a strong indication of a primary infection of more than 3 months, whereas the detection of weak avidity antibodies is a strong indication of a primary infection of less than 3 months.

 

 

A study conducted to assess VIDAS CMV IgG avidity II maturation kinetics on 135 sequential samples from 31 patients1 confirmed a very good correlation to clinical diagnosis:

  • No misclassification of recent infections (< 3 months)
  • No misclassification of past infections (> 3 months)
  • Best correlation over time from onset of infection compared to other commonly-used assays
  • Most regular avidity maturation pattern

 


 

VIDAS® CMV IgG Avidity index following seroconversion:
an accurate reflexion of the CMV–IgG avidity maturation kinetics

Adapted from Vauloup-Fellous C. et al.1


 

 

VIDAS® TOXO IgG Avidity

VIDAS TOXO IgG Avidity is a simple technique which enables weak avidity antibodies to be differentiated from high avidity antibodies. The detection of high avidity antibodies is a strong indication of a primary infection dating back more than 4 months.
 


 

*This result must be systematically confirmed using a second sample collected two to three weeks later.

 

  • Only FDA cleared Toxo IgG avidity test
  • Best performance for the exclusion of primary infection in patients with IgM and IgG positive results compared to other avidity assays2,3
  • The VIDAS system holds a reference position in the field of toxoplasmosis serology


Percentage of high IgG avidity values with different techniques:
VIDAS® Toxo IgG Avidity identifies more old infections than other commonly-used test
s

Adapted from Murat et al.3

 

See package inserts for performance details.

 

Ease of use and cost-effectiveness

  • Single-dose, ready-to-use tests
  • Performed on the automated VIDAS® immunoanalyzers, recognized worldwide for their flexibility, ease-of-use, reliability and 24/7 availability
  • Small packaging volumes
  • Ideal solution for small routine, confirmation of positive IgM, and IgG avidity testing

 

References:

  1. Vauloup-Fellous C.,et al. J Clin Virol (2012).
  2. Villard O, et al. Clinical and Vaccine Immunology Journal. February 2013. | Evaluation performed by an independent network of experts
  3. Murat J-B., et al. Clinical and Vaccine Immunology Journal. August 2013.
VIDAS® ToRC panel
Parameter Reference Tests/kit Sample type Sample volume Time to result Calibration frequency
CMV IgG 30 204 60 Serum 100 µL 40 minutes 14 days
CMV IgM 30 205 30 Serum 100 µL 60 minutes 14 days
CMV IgG Avidity II 41 3557 30 Serum 2 x 100 µL 40 minutes No calibration
Rub IgG II 30 221 60 Serum, plasma 100 µL 40 minutes 14 days
Rub IgM 30 214 30 Serum 100 µL 60 minutes 14 days
Toxo IgG II 30 210 60 Serum, plasma 100 µL 40 minutes 14 days
Toxo IgG Avidity 30 222 30 Serum, plasma 2 x 100 µL 40 minutes No calibration
Toxo IgM 30 202 60 Serum 100 µL 40 minutes 14 days
Toxo Competition 30 211 60 Serum, plasma 125 µL 40 minutes 14 days

 

Find more technical details on resourcecenter.biomerieux.com.

Consult your local bioMérieux representative for product availability in your country.

 

Related Publications

  • Murat J-B., et al. Comparison of the Vidas System and Two Recent Fully Automated Assays for Diagnosis and Follow-Up of Toxoplasmosis in Pregnant Women and Newborns. Clinical and Vaccine Immunology Journal. August 2013.
  • Villard O, et al. Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies. Clinical and Vaccine Immunology Journal. February 2013.

ToRC testing during pregnancy

 

Tools for laboratories

  • Protect your Child: Ask about Toxoplasmosis!
  • Protect your Child: Ask about Rubella!
  • Protect your Child: Ask about CMV!

These patient information leaflets are available on resourcecenter.biomerieux.com.  Register now!

 

Find more scientific and educational resources on resourcecenter.biomerieux.com.

Pioneering Diagnostics